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Abstract 
Background: The intra-erythrocytic development of the malarial parasite is dependent on 
active uptake of nutrients, including human serum albumin(HSA), into parasitized 
erythrocytes(pRBCs). We have designed HSA-based nanoparticles as a potential drug-
delivery option for antimalarials. Methods: Artemether-loaded nanoparticles(AAN) were 
designed and antimalarial activity evaluated in-vitro/in-vivo using Plasmodium 
falciparum/Plasmodium berghei species, respectively. Results: Selective internalisation of 
AAN into Plasmodium-infected RBCs in preference to healthy erythrocytes was observed 
using confocal-imaging. In-vitro studies showed 50% dose reduction for AAN as compared to 
drug-only controls to achieve IC50 levels of inhibition. The nanoparticles exhibited 2-fold 
higher peak drug concentrations in RBCs with antimalarial activity at 50% of therapeutic 
doses in P.bergei-infected mice. Conclusion: HSA-based nanoparticles offer safe and 
effective approach for selective targeting of antimalarial drugs.
Key words: Human serum albumin nanoparticles, artemether, malaria, parasitized 
RBCs 
1. Introduction 
     Malaria is a global health priority with more than 3 billion people at risk [1]. Effective 
treatment of malaria is hampered by the development and rapid spread of resistance to all 
known classes of antimalarials. Furthermore, the non-specific targeting of intracellular 
parasites result in high doses of therapeutic agents being used with higher incidence of 
related toxicities. Upon invasion by the malaria parasite, the host erythrocyte cell membrane 
undergoes major remodelling in structure, composition and function [2]. The intra-
erythrocytic parasites import nutrients for their development and export proteins and lipids 
into the host cell cytoplasm. This transportation occurs through New Permeability Pathways 
(NPPs), which selectively increases the permeability of the cell membrane of parasitized red 
blood cells (pRBCs) to a wide range of low molecular weight solutes [3]. An interconnected 
network of tubovesicular membranes (TVMs) is postulated to be responsible for the import 
of small molecules, whereas secretary cleft and lipid rafts may play a significant role in 
macromolecular transport in pRBCs [4]. Certain macromolecules like dextran, Protein A and 
IgG2 antibody are known to have direct access to the parasite through the “parasitophorous 
		
duct,” a tubular membranous structure that extends between the parasitophorous vacuolar 
membrane and the erythrocytic membrane [5-7].  These changes are of interest for 
antimalarial chemotherapy, as possible routes for targeting parasiticidal drugs into pRBCs. 
 
     Nanocarrier-based systems are providing new and powerful opportunities for targeting 
malaria-infected erythrocytes for the treatment of the disease [8, 9]. The overall goal for 
effective antimalarial therapy is the achievement of high intra-cellular drug concentrations in 
pRBCs. This would require the drug to cross multiple membrane barriers to access the intra-
parasitic targets, including the host erythrocyte membrane (HEM), the parasitophorous 
vacuolar membrane, the parasite plasma membrane and the food vacuolar membrane or 
endoplasmic reticulum membrane [10]. 
 
     Human serum albumin (HSA) is a non-toxic, non-immunogenic, biocompatible and 
biodegradable protein and has been widely used to design nanoparticles for drug delivery, 
and includes the commercially available nanoparticle albumin-bound (nab) paclitaxel, 
Abraxane™ [11]. In addition, HSA, an endogenous transport protein with multiple drug 
binding sites can act as a versatile drug carrier and offer various possibilities of surface 
modification by appending ligands to modify pharmacokinetics, enhance stability, prolong 
circulation half-life, alter drug release or act as a targeting agent [12,13]. Notably high 
specificity and affinity interaction of native serum albumin with the parasitized erythrocytes 
have been reported [14]. Significantly, biotin-labelled and radio-iodinated HSA when added 
in vitro to malaria parasite cultures exhibited uptake, access to the parasite membrane through 
a membrane network and degradation in the parasite [15].  We took advantage of these 
features to use HSA as a nano-carrier for targeting anti-malarial drugs to pRBCs. The use of 
HSA to prepare nanoparticles for antimalarial drugs is an adept concept for selective 
targeting to pRBCs. 
 
     Artemether (ATM), a fast acting blood schizonticide is used as the current first-line 
therapy for severe multi-drug resistant malaria [16]. However, a very short half-life and poor 
aqueous solubility limits the clinical efficacy of this drug [17]. Currently, an oil-based 
		
injectable formulation for intramuscular administration is available commercially. However, 
its use is limited due to its non-defined and erratic absorption. A suitable vehicle for 
intravenous delivery of ATM is urgently needed, especially for treating severe and cerebral 
malaria. HSA binds strongly to artemisinin and its derivatives through thiol and amino groups 
[18], paving the path to the development of artemether-loaded HSA-based nanoparticles 
which will open up opportunity for intravenous administration of artemether. 
 
     The aim of the present research was to develop and characterize HSA-based artemether 
nanoparticles for parenteral delivery and investigate their antimalarial efficacy and selective 
targeting to pRBCs. These nanoparticles were fabricated systematically using Quality-by-
Design (QbD) approach. The nanoparticles were characterized for morphology, particle size, 
polydispersity index (PI), zeta potential, differential scanning calorimetry (DSC), X-ray 
diffraction (XRD) and Fourier transform infrared spectroscopy (FTIR) analysis. Their 
antimalarial efficacy was evaluated  in vitro and in vivo using Plasmodium falciparum and 
Plasmodium berghei species, respectively. Pharmacokinetic studies after single intravenous 
injection were carried out in parasitized mice model to determine intra-cellular drug 
concentration in the RBCs. Confocal microscopy imaging was used to examine the entry of 
these nanoparticles selectively in pRBC in preference to non-infected RBCs. To best of our 
knowledge this is the first report of selective targeting of pRBCs using HSA based 
nanoparticles.
2. Experimental 
2.1 Materials  
     Artemether was obtained as a gift sample from V. S. Internationals. HSA (Alburel) was 
purchased from Lifeline Pharmaceuticals, India. Absolute ethanol and polysorbate 80 were 
purchased from S. D. Fine chemicals Ltd. India. Trehalose was gift sample from Signet 
Chemicals, India. SYBR Green, hypoxanthine, gentamycin, formaldehyde solution, albumin 
bovine serum fraction V and 4′6-diamino-2-phenylindole were procured from Sigma 
Aldrich, UK. Dextrose anhydrous, was sourced from Fisher Scientific, UK and Hepes 
medium was from Gibco, Life Technologies, UK. All solvents and chemicals used were of 
analytical grade.  
		
 
2.2 In vitro culture of Plasmodium 
     Plasmodiun falciparum parasites (strain 3D7 and K1) were grown in O+ve human RBCs 
in RPMI 1640 [+] L-glutamine, [+] Hepes medium supplemented with 5 mg/L albumin 
bovine serum fraction V, 50 mg/L hypoxanthine, 5 ml/L of 40% glucose and 50 mg/L of 
gentamycin (in PBS) in accordance with Read and Hyde [19]. Continuous culture of parasites 
at 5% haematocrit was carried out in 25 or 12.5 cm2 flasks, in final culture volumes of 10 ml 
and 5 ml respectively with sub culturing at 48 and 72h intervals. Synchronization of parasite 
stages was achieved by adding sorbitol solution (5% w/v in distilled water filtered through a 
0.22 µm filter) to the parasite pellet with a 5 min incubation. The culture was centrifuged at 
3,000 rpm for 5 minutes and the supernatant discarded. The pellet was washed three times in 
complete RPMI prior to re-suspension at the appropriate haematocrit. Preliminary estimation 
of parasitaemia was carried out using Giemsa-stained thin blood smears. Culture flasks were 
gassed with a 5% CO2, 5% O2, 90% N2 air mixture (BOC Limited, UK) and incubated at 
37°C (Leec 190 CO2, Leec Limited, UK).  
 
2.3 In vivo culture of Plasmodium   
     The P. berghei ANKA strain was used for in vivo evaluation of antimalarial activity. The 
strain is well characterised with high mortality in mice. The parasites kept in liquid nitrogen 
were thawed (at 37 °C) and parasitic culture was maintained in live mice through serial blood 
transfusion in fresh animals every 4 days. Animal experiments were carried out as per the 
protocols (CUSCP/IAEC/43/2012 and CUSCP/IAEC/31/2013) approved by Institutional 
Animal Ethics Committee of SNDT Women’s University, Mumbai. Research was conducted 
in accordance with guidelines on animal use and care and followed internationally accepted 
principles for laboratory animal use and care. Swiss albino mice of either sex aged 9-10 
weeks and weighing 22-27g were used for the experiment. The animals were quarantined at a 
temperature of 22±30 C and 65% relative humidity and were fed a standard pelleted diet and 
provided with clean drinking water, throughout the experiment. 
 
2.4 Development of artemether-loaded HSA nanoparticles  
		
     Artemether-loaded HSA nanoparticles (AAN) were prepared using the desolvation 
technique [20-22] followed by high-pressure homogenization. Briefly, HSA (Alburel) was 
diluted with water to obtain the desired concentration (2% w/v) and pH was maintained at 
neutral. The drug was dissolved in a mixture of ethanol (40% v/v) and polysorbate 80 
(3%w/v), which was slowly injected in the protein solution. The dispersion was cross-linked 
by heating and homogenised in a high-pressure homogeniser (Niro Saovi Panda Plus). The 
nanoparticles thus obtained were lyophilised in presence of trehalose as cryoprotectant in a 
freeze dryer (Martin Christ Epsilon 2-4LSC). A 48 hour cycle was divided into three phases 
of 6, 18 and 24 hours for the stages of freezing, main drying and final drying, respectively 
(Table S1). Blank nanoparticles (BAN) were prepared using exactly the same protocol 
without addition of any drug. Rhodamine B (2.5µg) was covalently bound to AAN (1 ml) 
using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC)/N-
hydroxysulfo-succinimide (sulfo-NHS) reaction with incubation at room temperature for 3 h 
to prepare rhodamine labelled nanoparticles [23, 24]. The labelled nanoparticles were 
subjected to dialysis against deionized water to remove any excess dye. Briefly 1 ml 
Rhodamine B tagged nanoparticles were put in dialysis membrane (3K MWCO) bag 
and suspended in beaker filled with 1000ml deionised water with continuous magnetic 
stirring for 1 h. 
     Systematic optimization of the formulation was carried out using the QbD approach [25]. 
The Ishikawa diagram was used to determine the critical quality attributes (CQA) of the 
entire process (Fig 1). The method was optimised for materials, process and environment 
related factors (Table 1) to correct the CQAs during the development. Apart from 
conventional optimisation with one factor at a time, two 32 factorial designs (9 runs each) 
were applied to optimise the material related parameters. Design I investigated the effect of 
HSA (at three levels; 1,2 and 3% w/v) and solvent concentration (at three levels; 20,30 and 
40% v/v) and design II investigated the effect of HSA (at three levels; 1,2 and 3% w/v) and 
surfactant concentration (at three levels; 3, 5 and 7% w/v) on the particle size of the 
nanoparticles (Table 2). Design Expert 8.0 was used to build response surface curves. Process 
related parameters, i.e., homogenisation pressure and number of homogenisation cycles were 
optimised by varying the homogenisation pressure from 200 to 1400 bars with 1 to 20 
		
homogenisation cycles (20 runs Table S2). Environment related factors like pH, type and 
concentration of cryoprotectant were also optimised.  
2.5 Fluorescence spectroscopy for determination of binding of artemether to HSA  
Fluorescence spectroscopy helps in understanding the residues that are involved in the drug-
carrier interaction. Fluorescence spectra of HSA alone and in the presence of different 
concentrations of artemether were taken at excitation wavelength (λex) of 280nm and 
emission wavelength (λem) from 290 to 400nm on Perkin Elmer LS55 fluorescence 
spectrometer. Fluorescence spectra of blank HSA nanoparticles (BAN) and AAN were also 
recorded. The fluorescence quenching data was analysed according to the Stern–Volmer 
equation [26, 27]                                                     
 F0/F = 1+Ksv [Q]  
 
F0 and F denote fluorescence intensities in the absence and presence of quenchers 
respectively. Ksv is the Stern-Volmer constant and [Q],  the quencher concentration. 
 
2.6 Characterisation of artemether-loaded HSA nanoparticles  
2.6.1 Particle size and Polydispersity index 
     AAN was characterised for mean particle size and PI using photon correlation 
spectroscopy (PCS) technique employing N5 Beckman particle size analyser Inc., USA. All 
measurements were carried out at a fixed angle of 900 at 200C using double distilled water as 
dispersant. The averaged values  three measurements are presented. 
2.6.2 Morphology 
     The microstructures of AAN particles were observed using transmission electron 
microscope (TEM) (Philips CM 200). Initially, sample diluted with double-distilled water 
was deposited on film-coated copper grids and allowed to dry overnight at room temperature. 
The dried samples were visualized under TEM. Size and morphology of lyophilised 
nanoparticles were examined using a field emission scanning electron microscope (SEM) 
(Model JEOL JSM-7600F). AAN particles were first coated in gold to minimize the effect of 
heat during high power magnification. 
 
		
2.6.3 Differential Scanning Calorimetry (DSC) 
     DSC measurements on ATM, HSA and AAN were performed using a Q200 TA 
instrument (New Castle, Delaware, USA). The heating runs were performed from 30°C to 
200°C at  10.0°C/min. An empty aluminium pan was used as a reference. 
 
2.6.4 Fourier Transform Infrared (FT-IR) spectroscopy 
      The interaction between the drug and carrier and the encapsulation of drug was evaluated 
using FT-IR spectroscopy using JASCO FTIR 5300 Spectrometer with TGS detector (MD, 
USA) over the scanning wavelength range of 4000 – 400 cm-1. Potassium bromide disc 
method was employed to obtain FT-IR spectrums of AAN as well as the individual 
components.  
2.6.5 X-ray Diffraction (XRD) Studies 
     XRD studies of ATM and AAN were performed using Philips Expertpro MPD 
diffractrometer (PAN analytical Inc. Germany) with resolution of 0.001 A0. The samples 
were radiated using a Cu target (λ = 1.54056 Å) and scanning angles ranged from 70 to 700 of 
2θ. 
2.6.6 Determination of entrapment efficiency 
      Entrapment efficiency was determined by separating the nanoparticles from aqueous 
dispersion by ultracentrifugation (30000g at 40 C for 1h) and the amount of free drug in the 
clear supernatant was analysed by UV-spectroscopy (UV 2450, Shimadzu, Japan) [16]. The 
encapsulation efficiency was calculated by using the following equation: 
    W – w   x    100 
        W 
where W = amount of ATM initially added and w = amount of ATM present in the 
supernatant 
 
2.6.7 In vitro Drug release  
      In vitro drug release study was performed in modified USP type II apparatus (Electrolab, 
India Pvt Ltd.). 3ml of AAN dispersion or reconstituted lyophilised AAN nanoparticles were 
enclosed within cellulose acetate  dialysis bag (3K MWCO) and placed in 200 ml of 
		
phosphate buffer saline (pH 7.4): ethanol (50:50) as dissolution medium to maintain sink 
conditions The medium was continuously stirred at 100 rpm and maintained at 37±5oC. 5ml 
aliquots were  withdrawn at predetermined time points (0.5, 1, 2, 4, 6, 8 and 24 h) and were 
replaced with the same volume of dissolution media. The concentration of drug released was 
analysed by UV Spectroscopy (UV 2450, Shimadzu, Japan) [17]. 
 
2.7 In vitro erythrocyte toxicity study 
      Infection with P. falciparum result in erythrocyte rupture during its intra-erythrocytic life 
cycle causing haemolysis leading to anaemia in severe conditions [28]. For an antimalarial 
drug delivery system, it is important to have action targeted specifically on pRBCs with no 
harm to the uninfected erythrocytes. The in vitro erythrocyte toxicity study determines the 
toxicity potential of the system on the uninfected erythrocytes on intravenous administration.  
     The test was performed using varying dilutions of AAN in normal saline (1X, 10X and 
100X). Polysorbate 80 (3% w/v) and Triton X 100 (2% w/v) in normal saline were used as 
reference and positive control respectively. 100µl of the prepared human RBCs were 
incubated with 900µl of the test solutions for 30 minutes. The reaction was stopped by 
addition of glutaraldehyde. The tubes were centrifuged to separate the debris and the 
supernatant was analysed for the haemolytic activity by measuring the absorbance at 540nm 
by UV spectrophotometry (UV 2450, Shimadzu, Japan).  The percent haemolysis was 
calculated by the formula: 
% Haemolysis =   Absorbance of sample - absorbance of control                 x   100 
                             Absorbance of Triton X 100 – absorbance of control 
 
2.8 In vitro susceptibility assay  
Antimalarial drugs are maximally active on the mature trophozoite stage of parasite 
development. In vitro susceptibility has been correlated with the initial stage of the parasite, 
with isolates predominantly at the trophozoite stage having a twofold increase in IC50s 
compared to those of parasites predominantly at the ring stage [29,30]. The in vitro 
antimalarial efficacy was therefore assessed using synchronised trophzoite stage cultures of 
P. falciparum (K1) parasite strains reported previously [31]. 5 mM stock solution of 
		
artemether (MW 298.38) in DMSO (ATM) was used to produce a dilution series for the dose 
response curve. AAN and BAN nanoparticles were reconstituted aseptically with sterile-
filtered double-distilled water. 0.2ml of the P. falciparum culture (5% haematocrit and 0.5% 
parasitaemia) was seeded in a 24-well plate and formulations and drug solution added along 
with complete media. The drug dose range was tested at 0.78, 1.56, 3.13.6.25.12.5 and 25 nM 
concentrations. The plates were incubated for 48h at 37oC and parasitaemia was determined 
by SYBR green-based flow cytometry methods as described previously Briefly, triplicate 
drug/nanoparticle treated parasite cultures (100µl each) are transferred to Eppendorf tubes 
and washed in 1 ml PBS, and centrifuged at 1400 rpm for 90 secs. The pellet is resuspended 
in 1 ml 2.5 x SYBR Green 1 and incubated in the dark for 20 mins at room temperature. 
Samples were centrifuged as described and re-suspended in 250 µl of a fixative solution of 
0.4% formaldehyde solution and incubated at 4oC for 15 mins. The pellets were washed three 
times in PBS and suspended in 1 ml of PBS for flow cytometric analysis on a BD 
FACSVerse flow cytometer (USA). 50,000 events were recorded for each sample using the 
FITC channel and fluorescent intensity recorded. Percent inhibition was calculated against 
the drug-free control. 
 
2.9 Determination of cellular uptake of nanoparticles by confocal microscopy 
      Synchronized ring stage parasite cultures (200 µl) were incubated with Rhodamine B-
labelled AAN (25 µl) along with complete media (1ml) in a 24-well cell culture plate, at 
37ºC. The cellular uptake was observed at pre-determined time points of 15 min, 1 h and 24 
h. The cells were washed with RPMI-1640 culture medium and stained with parasite nucleic 
acid stain 4′6-diamino-2-phenylindole (DAPI) for 20 mins to distinguish pRBCs from 
normal RBCs. At each of the time points, a small sample (5 µl) was removed from a stock 
culture of pRBC and wet mounted on a clean glass slide with a coverslip placed on it for 
examination. The cellular uptake was observed at a magnification of 100X using confocal 
laser scanning microscope (ZEISS LSM 510 META, Germany) at an excitation wavelength 
of 540 nm and an emission maximum of 625 nm. As a positive control, pRBCs were stained 
with DAPI to distinguish them from uninfected RBCs and observed at excitation maximum 
of 358 nm and emission maximum of 461nm. 
		
 
2.10 In vivo antimalarial efficacy in P. berghei infected mice  
      The lethal ANKA strain of P. berghei was used for the experiments [32]. Mice of either 
sex (average weight 25g) were infected by intraperitoneal inoculation of the parasite obtained 
from the donor mouse blood diluted with citrate phosphate dextrose containing 
approximately 5X107-infected RBCs/ml. The mice were randomly divided into various 
groups (n = 5) (Table 4). Post-infection, the animals were treated with AAN aseptically 
reconstituted using sterile saline at two dose levels 0.624mg/day and 0.312 mg/day 
(equivalent to 100 and 50% of therapeutic dose of artemether) for four consecutive days. In 
lack of marketed intravenous artemether injection, artesunate (ARS), which has been 
previously employed for comparison in developmental antimalarial intravenous products 
[33,34], was used as reference. Larinate, marketed intravenous ARS injection, was 
reconstituted using the provided diluent under aseptic conditions and injected at same dose 
levels as AAN. Blank nanoparticles (BAN) were administered in volume equivalent to AAN 
containing 0.624mg of drug in AAN.  On day 0, 1, 5, 7, 10, 14 and 21, day thin blood smears 
were prepared by collecting a drop of blood from the tail vein. The blood smears were air-
dried, fixed in methanol and stained with Giemsa stain. The smears were then washed, air-
dried and observed under the microscope using an oil immersion lens and parasitaemia was 
assessed. The study parameters involved (i) number of surviving animals from each group on 
day 30 (ii) mean percent parasitaemia over time (in days) for all groups. Data was expressed 
as mean±S.D. and assessed by unpaired t-test using the Graph-pad Instat Demo version. A 
difference of P < 0.05 was considered as significant. 
 
2.11 Pharmacokinetics in P. berghei infected mice 
     The parasitized animals were divided into three groups of six mice per group. When 
animals reached parasitaemia of 50-60% the first group was administered AAN as single 
dose (35 mg/kg equivalent amount of artemether) intravenous injection. Artemether free drug 
being insoluble in water its solution was prepared by dissolving it in non clinical hydroaholic 
vehicle (ATM) [35] and administered intravenously to the second group while third group 
acted as control. At stipulated time interval of 10min, 30min, 1, 2, 4, 8, 10, and 24h, the 
		
animals were exposed to inhalation of anaesthetic ether and blood samples were withdrawn 
using retro-orbital puncture.. The blood samples were centrifuged at 2000 rpm for 10 min and 
the supernatant plasma and RBCs were collected in two separate clean Eppendorf tubes. To 
the 200µl plasma sample, 100µl of internal standard (artemisinin) and 700µl of acetonitrile 
was added and the contents of the tube were vortexed and then centrifuged at 2000 rpm for 
10 min using mini centrifuge (Hoefer, USA) [36]. Similarly for extraction from RBCs, to 200 
µl of RBC sample, 100 µl of internal standard, 20 µl ammonium chloride buffer (for 
haemolysis of RBCs) and 680µl of acetonitrile were added. The mixture was vortexed and 
centrifuged at 2000 rpm for 10 min (Hoefer mini centrifuge). The upper organic layer from 
each of the extractions was filtered and analysed using HPLC (Agilent 1200 series, 
Singapore) equipped with C18 column (Princeton SPHER ODS, 250 x4.0 mm; 5µ,) with 
PDA detector. Acetonitrile: water (75:25 v/v) was used as mobile phase at flow rate of 0.7 
ml/min. and detection wavelength was set at 210nm [37]. Each solution was injected in 
triplicate and mean peak areas were recorded for quantification for the drug. 
3. Results  
3.1 Development of artemether-loaded HSA nanoparticles  
     Basic methodology and all the essential material and process parameters required for 
development of nanoparticles were derived in reference to the Ishikawa Diagram (Fig 1). 
Risk identification and risk analysis of material, process and environment variables (Table 1) 
provided parameters for control strategy for the CQAs [25]. Optimization of the formulation 
was performed to reduce the risk of the CQAs to obtain a robust and reproducible 
formulation. 
       
      Concentration of HSA and Drug: HSA ratio was optimised based on the particle size and 
entrapment efficiency of the drug. Increasing the HSA concentration resulted in increase in 
particle size (Fig 2a) hence, 2% w/v concentration was found to be optimum showing 
negligible drug precipitation and lower particle size [20]. Incorporating ATM at drug: HSA 
ratio of 1:5 resulted in precipitation of drug while 1:20 ratio led to increase in particle size 
without added advantage in loading efficiency thus drug: HSA ratio of 1: 10 was found 
optimum (Table 3). ATM being highly water insoluble drug, incorporation of polysorbate 80 
		
stabilised the nanoparticles with positive effect on drug entrapment (Fig 2c) [38, 39].  
Concentrations of HSA, ethanol and polysorbate 80 were further optimized using two 32 full 
factorial designs. The P-values of 0.0009 and 0.0274 indicated that the models were 
significant. Reducing the HSA concentration and increase in ethanol concentration resulted in 
smaller particle size (Fig 2d) [40]. The blue region in the response surface curve (Fig 2e) 
shows the area of lowest particle size, which could be achieved at the optimum HSA and 
surfactant concentration levels  
  
          Increasing the pH (>7) of the HSA solution prior to desolvation decreased the particle size of 
the nanoparticles (Fig 2b), due to increased repulsion between the molecules preventing their 
aggregation. This observation is in good agreement with previously published literature [20, 
41]. However ATM precipitated at higher pH, therefore it was important to maintain the pH 
of the HSA solution at 7 throughout the process. This could be explained by different HSA 
conformations at different pH values. The standard HSA conformation “N” is present at 
neutral pH. A change to the “B” conformation occurs above pH 8 which might have lower 
affinity to ATM [42].  Similar observations have been earlier reported [43].  
 
            High-pressure homogenization was used to prepare HSA nanoparticles [44]. Effect of 
homogenization pressure and number of homogenisation cycles were seen to play an 
important role in determination of particle size. It was found that lower homogenisation 
pressures were sufficient to get the desired particle size (<100nm) and PI. Higher pressures 
led to increase in particle size [Supplementary data Table S2]. Though earlier reports have 
shown reduction in particle size with increase in homogenisation pressure for HSA 
nanoparticles,  a minimum particle size of 222.2 nm could only be achieved at high 
homogenisation pressures [45]. 
 
3.2 Freeze drying of nanoparticles 
       AAN was freeze-dried to get a free flowing stable product. Freeze-drying of AAN 
without cryoprotectant and with mannitol and lactose as cryoprotectants resulted in increased 
particles size and PI (Fig 3) [46]. Trehalose at 3% w/v concentration was found useful as 
cryoprotectant for lyophilisation of nanoparticles with neither a significant change in particle 
		
size (3a) nor in polydispersity index (Fig 3b). Trehalose is known to preserve the HSA 
nanoparticle during freeze-drying as it forms amorphous glass, which is reported to interact 
with amorphous protein in the freeze-dried cake [47]. 
 
3.3 Fluorescence spectroscopy for determination of binding of artemether to HSA  
     Fluorescence quenching of the single tryptophan residue in HSA was  used to measure 
drug-binding affinity [48]. When HSA is excited at 280 nm, fluorescence intensity around 
350 nm reflects changes of the microenvironment of tryptophan residue. Addition of ATM 
showed dynamic quenching of the fluorescence of HSA (Fig S4) and followed Stern Volume 
equation with Ksv of 1.755×104 L.mol-1 [26].  A strong decrease in the fluorescence intensity 
in the spectra of AAN nanoparticles (650a.u) was observed in comparison with the blank 
nanoparticles (900a.u) (Fig. 4) suggesting interaction of ATM and HSA. The quenching 
process also signifies the tertiary structural changes in HSA demonstrating binding of drug 
with HSA in the nanoparticulate formulation [49]. 
 
3.4 Characterization of the nanoparticles  
     Mean particle size of AAN was found to be 66.1nm (PI 0.090) by PCS and was in 
confirmation to that obtained from TEM and SEM (Fig 5) of the freeze-dried product (Fig 
5d) with zeta potential from -14.9 mV. TEM and SEM images both confirmed almost 
spherical morphology of AAN.  
 
      DSC thermogram of ATM and HSA exhibited endothermic peaks at 85.730 C and 126.970 
C respectively. AAN showed a shift in the peak to 160.450 C because of drug-albumin 
binding and formation of nanoparticles [20], although a small peak near the endothermic peak 
of the drug may be indicative of small amount of ATM present on the surface of HSA matrix 
(Supplementary data Fig S1). 
 
     XRD pattern of ATM shows the presence of sharp peaks indicating the crystalline nature 
of the drug. The XRD of HSA exhibited a broad reflection with no distinct peaks revealing 
the amorphous structure of HSA. Absence of sharp peaks of artemether and broad humps in 
		
the AAN graph indicated that the drug was successfully incorporated into the HSA 
nanoparticles and was present primarily in an amorphous form within the nanoparticles 
(Supplementary data Fig S2) [50]. However, some sporadic weak peaks in AAN might 
indicate that ATM might not be not fully shielded by protein side chains and small amounts 
present on the surface. This is in accordance with our DSC results and consistent with a 
previous study [51]. 
 
     All the characteristic peaks of HSA observed in the FTIR were retained in the AAN 
indicating no chemical modification in the structure of the protein. The spectra of AAN 
revealed the characteristic peaks of ATM with almost negligible shifts from which it may be 
deduced that artemether is entrapped within the HSA matrix and that the chemical structure 
of artemether does not change after encapsulation (supplementary data Fig S 3). Similar FTIR 
spectroscopy results have been demonstrated for encapsulation of bioactive molecules into 
albumin nanoparticles [40,52].  
 
     In vitro release curves (Fig 5) of ATM from AAN showed an initial burst effect followed 
by slow release. This could be because of the different ways in which the drug is loaded in 
the nanoparticles: adsorption and entrapment [53]. Lyophilisation of nanoparticles did not 
have any effect on the drug release and was similar to that obtained from nanoparticles prior 
to lyophilisation. 
 
3.5 In vitro erythrocyte toxicity study 
      ATM being practically insoluble, required polysorbate 80, a non-ionic surfactant to be 
incorporated in the formulation to improve its solubility and drug entrapment. Surfactants 
may cause damage to cell membranes of erythrocytes due to increases in membrane 
permeability [54] and therefore an in vitro erythrocyte toxicity test was carried out to evaluate 
biocompatibility of the nanoparticles  [55] Triton-X-100 (positive control) showed 100% 
haemolysis of erythrocytes throughout the incubation period. Though polysorbate 80 solution 
(3% w/v) exhibited haemolysis of 75.89% after 30 min incubation, AAN containing 3% w/v 
polysorbate 80 showed an erythrocyte haemolysis rate of only 9.92% (Fig. 6), demonstrating 
		
its safety. An earlier report by Joshi et. al., has shown very low erythrocyte haemolysis of 
NLC even at very high concentrations of surfactant [32]. This might be due to micelle 
formation of the surfactant at the nanoparticle and water interface, resulting in solubilisation 
of the drug and stabilisation of the entire system. Previous experiments have shown that a 
polysorbate 80 coating on the surface of HSA nanoparticles possess reduced toxicities and 
improved pharmacokinetic parameters of doxorubicin [56]. Clinically, upon administration, 
drugs injected intravenously are immediately diluted to a very large extent due to constant 
blood circulation and sink conditions provided by the body. To mimic in vivo conditions, 
diluted formulations were also tested for their haemolytic potential. AAN showed a 
haemolysis of 6.24% when diluted 10 times and 6.12% when diluted 100 times at the end of 
30 minutes (Fig 5).  
 
3.6 In vitro susceptibility assay 
      Treatment of P. falciparum cultures with ATM and AAN demonstrated a dose-dependent 
anti-parasitic effect while BAN, the HSA nanoparticle without any drug, failed to show any 
effect (Fig. 7) [57]. AAN displayed optimal enhancement of anti-malarial activity in a 
concentration range of 3.13 to 12.5 nM. At concentrations that were too low to effectively kill 
the parasite, insignificant differences were observed in the efficacy of drug solution and 
particles. Similarly, when drug concentrations were high enough to overcome rate-limiting 
diffusion and provide intracellular parasiticidal concentrations, the efficacy of particles was 
no different from that of the drug in solution. However, in a window of intermediate 
concentrations, the advantages of drug targeting using nanoparticles were unambiguously 
apparent. Maximum difference in inhibition of parasitaemia was evident at 6.25 nM drug 
concentrations of ATM demostrating significantly (p<0.001) higher antimalarial activity with 
AAN as compared  drug solution. IC50 values of AAN and ATM solution were 5.4 nM and 
12.08 nM  respectively, evidencing improvement in efficacy at comparative IC50 dosages .  
 
3.7 Determination of cellular uptake of nanoparticles by confocal microscopy imaging 
     Nanoparticles attached on the surface of erythrocytes possess extended circulation time in 
the body [58]. Nano-sized particles (≤200 nm) have been shown to enter the RBC however; 
		
the translocation mechanism is not clear and remains controversial [59] Therefore, study was 
carried out to analyse actual entry of the nanoparticles into the plasmodium-infected 
erythrocytes. 
 
     DAPI staining helped in differentiating between parasitized and non-parasitized RBC in 
the co-cultures since DNA of the parasite is stained blue which is only present in the pRBC 
(Fig.8) [60]. Rhodamine-labelled AAN incubated with Plasmodium-infected RBCs showed 
time-dependent uptake selectively by pRBCs as evident by co-located red fluorescence in 
DAPI stained cells. (Fig 8). The uptake starting at as early as 5 minutes of incubation and the 
fluorescence was found to persist till the rupture of pRBC. The uptake of nanoparticles was 
confirmed by Z-stacking of the confocal images which showed presence of florescence due 
AAN in various sections of the pRBCs (Fig S5).  All the confocal images confirmed that 
nanoparticles do not penetrate the normal non-infected RBCs as was evident by absence of 
red florescence of rhodamine-labelled nanoparticles in these cells (Fig 8). 
 
3.8  In vivo antimalarial efficacy in P. berghei infected mice  
     Nanostructured lipid carrier [32] and lipid nanoparticles [61] of artemether have shown 
improved antimalarial activity in P. berghei model. Peter’s four-day suppressive test was 
performed on AAN at two dose levels viz, 100 and 50% of therapeutic dose of the drug using 
P. berghei-infected Swiss albino mice. Due to absence of any intravenous injection for 
artemether, Larinate (artesunate injection), which is administered as intravenous injection 
was used as the reference.  
 
      The control group showed highest parasitemia at all-time intervals with maximum of 
72.13% on day 10 with all mice found to be dead after 10th day. As compared to the control 
group, all the other groups showed reduction in the parasitemia during the course of study (p 
< 0.001), analysed by one-way ANOVA followed by Tukey’s multiple comparison test. 
Marketed formulation showed reduction in parasitemia (23.46%, day 21) as compared to 
control at 100% dose level, however the reduction in parasitaemia was much less (46.34%, 
day 21) and the survival rate of animals was reduced to half (Table 4) when the dose was 
		
reduced to 50%. Parasitaemia with AAN was found to be 13.21% at 100% dose and 13.71% 
at 50% dose level at the end of 21st day of the experiment. AAN showed significantly less 
(p<0.001) parasitaemia as compared to marketed intravenous injection of artesunate at both 
the dose levels (Fig 9). Blank nanoparticles showed reduction in the parasitaemia (30.48%) 
on 21st day as compared to the control. Previously Blank NLC (placebo vehicle) has also 
shown reduction in the parasitaemia [32]. The reason for the activity is not known since none 
of the excipients is known to have any antimalarial activity. The surfactant used in the 
formula might by responsible for the parasitic cell haemolysis due to increased permeability 
of the parasitized cell, which might have resulted in the activity. Interestingly albumin has 
been reported to reduce mortality when given as adjunct therapy in children with severe 
malaria (62).  
3.9 Pharmacokinetics and erythrocyte drug concentration in P. berghei-infected mice 
     AAN showed higher drug concentrations in the erythrocytes and deliver their payload to 
the target cell more efficiently than the molecular drug solution. AAN showed two times 
higher peak drug concentration in the RBCs as compared to ATM solution (Fig 10a). This is 
consistent with the results obtained in in-vitro P. falciparum studies, which showed increased 
intracellular uptake by pRBCs and higher inhibition of parasitaemia by AAN. This is also 
reflected by higher AUC024 (p< 0.05) in the RBCs after administration of AAN 
(1017.5±107µg.min/ml) as compared to ATM solution (554.5±68µg.min/ml)). After 
intravenous administration, AAN and ATM showed high initial plasma concentrations 
followed by constant decline with very low concentrations remaining at the end of 10h and 
no drug in plasma at 24h. AAN revealed lower drug levels in plasma as compared to ATM 
probably because of partitioning more into RBCs (Fig. 10 b)
4. Discussion 
     Clinical management of severe and cerebral malaria remains a challenge with varying 
degrees of success even with parenteral administration of potent anti-malarial agents. Drug 
delivery strategies that can target the antimalarial drugs selectively to the pRBCs can 
potentially reduce drug exposure to non-target sites, delivering high drug concentrations to 
the infected cells and reducing the risk of drug resistance. In this study, we show HSA 
		
nanoparticles to be selectively taken up by pRBCs leading to higher local drug concentrations 
and improved antimalarial efficacy.  
     Robust HSA nanoparticles were developed using the QbD approach. An industrially 
feasible and scalable process of high-pressure homogenisation was used to fabricate the 
nanoparticles [44]. ATM being water insoluble is presently available as an oily intramuscular 
injection. HSA showed strong binding to artemether (Fig 4f) and with resultant physical 
linkages facilitated nanoparticle formation. Addition of polysorbate 80 (3% w/v) stabilised 
the nanoparticles and prevented drug precipitation, leading to formulation of an aqueous 
injection of ATM with high drug loading [39].   Addition of polysorbate 80 had no 
discernible adverse effect on the cell membrane of erythrocytes, as demonstrated by low 
haemolytic activity (<10%), which was further reduced on dilution (Fig 5). The nanoparticles 
can be considered safe for intravenous administration. 
 
     It is important to control the size of the prepared nanoparticles because smaller sized 
particles improve the bioavailability, with increased ability to enter cells. It has been reported 
that only NLCs <400 nm diameter were taken up by pRBCs. [63]. In another study, it was 
determined that fluorescent latex beads >172 nm did not access intracellular parasites [7]. In 
our study we aimed to prepare nanoparticles having particle sizes less than 100 nm.  HSA 
concentration critically affected the particle size and drug entrapment. While higher HSA 
concentrations led to increase in particle size, lower concentrations decreased the drug 
entrapment. The average size of the particles also decreased with increase in the percentage 
of added ethanol [40, 64]. In this context, the optimised nanoparticles with Drug:HSA ratio of 
1:10 at 40% ethanol concentration as desolvating agent produced the smallest nanoparticles 
with highest drug loading (77.6%). Low homogenisation pressure 200 bar (10 cycles) 
followed by 5 cycles at 400 bar was sufficient to yield mean particle size of 66.1 nm and PI 
of 0.090. Higher homogenisation pressures resulted in a larger particle size. This can be 
explained as follows; the additional energy input resulted in higher kinetic energy of the 
particles with subsequent coalescence. Once the maximum dispersitivity has been reached 
additional energy put into the system cannot be used for further dispersion of nanoparticles. 
The energy put in can only accelerate the velocity of the particles, giving them adequate 
		
kinetic energy to overcome the stabilization resulting in aggregation and increase in mean 
size [65]. 
 
     Since ATM is known to be moisture sensitive, drug freeze-drying was investigated to 
retain the stability of AAN. Freezing often induces many destabilizing stresses for 
nanoparticles. Formation of ice crystals that can mechanically destabilize nanoparticles and 
increased interaction due to enhanced nanoparticle concentration leading to aggregation or 
fusion are some of the phenomena observed during freeze drying [66]. Trehalose as an 
additive seems to provide sufficient protection from lyophilization of HSA protein, 
contributing to maintaining stability in the solid state [67]. Trehalose containing formulations 
were superior to mannitol and lactose, exhibiting minimal increases in nanoparticle size  and 
PI following the freeze-drying procedure (Fig 3a,3b) [68].  
 
      The release of drug from AAN was characterised by a biphasic release pattern with an 
initial burst release (t50% - 4.6h) followed by sustained drug release (t90% - 25.3h) (Fig 5e). 
The initial fast release is attributed to the weakly interacted drug associated with surface of 
the nanoparticles. Subsequently, the entrapped ATM released from the core of the 
nanoparticles in a sustained manner due to the diffusion of drug across the albumin matrix, 
would provide the possibility of continual drug effect. A similar phenomenon was observed 
previously in albumin nanoparticles [69-71]. However the association of the drug with the 
carrier material in competition with other carriers such as plasma proteins, lipids, and cell 
membranes plays an important role for the performance in vivo [72]. 
 
     In vitro susceptibility assays in P. falciparum demonstrated significantly (p<0.001) higher 
antimalarial activity with AAN as compared drug-only control as demonstrated by the lower 
IC50 values of AAN. This was confirmed by in vivo studies where AAN showed high 
antimalarial activity even at 50% dose in P. berghei infected mice. While the chemo-
suppression was reduced from 76.54% to 53.66% when free ARS dose was reduced to 50%, 
chemosupression did not change significantly (p > 0.05) showing equal activity (86.79 and 
86.29%) at 100 and 50% doses respectively with AAN. 
 
		
     Confocal images clearly discriminated the selective uptake of Rhodamine-labelled AAN 
particles by pRBCs and not by normal RBCs. The amount of nanoparticles entering the 
pRBC was found to increase with time. It is a well-known fact that, mature erythrocytes do 
not display endocytosis and no pathways are evident for up taking macromolecules by these 
cells [73,74]. But contrary to this, uptake of ferritin claiming that Plasmodium-infected red 
cells are capable of endocytosis have been reported [75]. Many changes occur in the host cell 
membrane during intracellular malarial parasite development with extensive degradation of 
spectrin, allowing endocytosis in pRBCs [76,77]. Parasites are capable of enhancing the 
permeability of cell membranes in the host through NPP [78,] and TVM [79] allowing 
nutrients access to the parasite.  This increased permeability differs from the native transport 
systems of the normal erythrocyte [80,81]. Membrane-impermeable macromolecules in the 
external medium have been shown to bypass the host cell cytosol to reach intracellular 
parasites [82,83]. Though internalisation mechanisms remain to be elucidated, it is speculated 
that HSA nanoparticles would follow similar uptake pathways, as HSA which has been 
reported to have direct access through the parasitophorous duct [5,6,15]  into the pRBCs as a 
nutritional requirement [15,84,85].  Pouvelle et al., have demonstrated the presence of tubular 
prominences, which develop in the cytoplasm of the pRBC that link up with the host cell 
membrane to form a transient or stable  duct, providing a means of direct access between the 
parasite and the external milieu [86]. An alternative concept of a 'metabolic window’ that 
forms during the ring stage of asexual parasite maturation, provides ‘contact sites’ between 
the HEM and the PVM [87]. The altered membrane permeability coupled with capability for 
endocytosis could be key factors responsible for the entry of the nanoparticles selectively into 
the pRBCs [2, 5, 75, 80]. 
 
    Previously, Hasan et al., reported on the entry of stearylamine liposomes into the pRBC 
when observed using fluorescent microscopy [88]. Choloroquine liposomes loaded with 
quantum dots, covalently functionalized with oriented, specific half-antibodies against P. 
falciparum have been found to dock to pRBC plasma membranes and release their cargo into 
the cell [89]. More recently polymers poly(amidoamines) AGMA1 and ISA23 have  
exhibited preferential binding to and internalization into P. falciparum and P. yoelii  infected 
RBCs [90]. However safety of these systems have not been definitively established. HSA 
		
being endogenous, stable, biocompatible and already commercially exploited for other 
applications has a distinct advantage over these nanosystems and could be a safer, new tool  
for targeting drugs to Plasmodium infected cells.  Improved activity and the associated 
reduction in parasitaemia with AAN,  could be attributed to parasite clearing as a result of 
selective cellular uptake of nanoparticles by pRBCs as observed by confocal microscopy.  
 
5. Conclusion 
      In conclusion, biodegradable artemether-loaded HSA-based nanoparticles were developed 
as an intravenous drug delivery system for the treatment of malaria. Robust formulation with 
reproducible particle size was successfully obtained employing the QbD approach.  . In vitro 
studies using P. falciparum showed a 50% reduction in IC50 values of AAN when compared 
with drug only controls. AAN showed marked less parasitaemia as compared to marketed 
intravenous injection of artesunate and showed equivalent antimalarial activity at half the 
therapeutic dose. Uptake of nanoparticles by pRBCs was demonstrated by higher intracellular 
drug concentration in the erythrocytes as shown by the pharmacokinetic studies in the 
parasitized mice. Confocal imaging confirmed the selective entry of the nanoparticles into 
pRBCs, but not healthy uninfected RBCs. A follow-up quantitative fluorescence-assisted cell 
sorting analysis study is proposed as part of further work.  Thus, HSA nanoparticles have 
shown significant potential to be used as a safe and effective drug delivery system for the 
treatment of malaria. As it permits intravenous administration and selective pRBC uptake, it 
can be a beneficial strategy in severe and cerebral malaria. 
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Executive Summary 
• Biodegradable artemether (ATM) loaded human serum albumin (HSA) based 
nanoparticles (AAN) successfully developed as an intravenous drug delivery system 
for the treatment of malaria. Robust formulation optimised for critical product and 
process parameters with reproducible particle size (<100nm) and high entrapment 
efficiency. 
•  Complete characterisation carried out in terms morphology, particle size, 
polydispersity index (PI), zeta potential, differential scanning calorimetry (DSC), X-
ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR)  and, in-vitro 
drug release  
• Fluorescence spectroscopy demonstrated binding of drug with HSA in the 
nanoparticulate formulation as seen by decrease in the fluorescence intensity in the 
spectra of AAN nanoparticles in comparison with the blank HSA nanoparticles 
• In vitro erythrocyte toxicity study established the safety for intravenous 
administration of AAN. 
• Selective internalisation of AAN into Plasmodium-infected RBCs (pRBCs) in 
preference to non-infected erythrocytes was observed using confocal imaging.  
• In vitro susceptibility studies with Plasmodium falciparum showed 50% dose reduction 
for AAN as compared to drug-only controls to achieve IC50 levels of inhibition.   
• The nanoparticles exhibited 2-fold higher peak drug concentrations in RBCs with 
antimalarial activity at 50% of therapeutic doses in Plasmodium. bergei-infected mice.  
		
• HSA-based nanoparticles could offer a safe and effective approach for selective 
targeting of antimalarial drugs Plasmodium infected cells. To best of our knowledge 
this the first report of selective targeting of pRBCs with HSA based nanoparticles. 
 
Table 1: Risk assessment for control of critical quality attributes for fabricating HSA 
nanoparticles 
Risk assessment related to 
Critical Quality Attributes 
Particle 
size 
Polydis
persity 
index 
Drug 
entrapmen
t 
Stability 
Materials 
HSA 
concentration 
High High High Medium 
Drug: HSA 
ratio 
Medium Medium High Low 
Solvent 
concentration 
High High Low Medium 
Surfactant 
concentration 
Medium Medium High High 
Process 
Homogenizatio
n pressure 
High High Medium High 
Homogenizatio
n cycles 
Medium Medium Medium Medium 
Environment 
pH High High        Low Medium 
Cryoprotectant High High Low Medium 
 
 
 
 
 
 
		
Table: 2 Concentration levels of the dependent variables in factorial designs 
 
Factors 
Factorial levels 
-1 0 +1 
HSA (%w/v) 1 2 3 
Solvent (%v/v) 20 30 40 
Polysorbate 80 
((%w/v) 
3 5 7 
 
Table 3: Optimisation of Drug: HSA ratio 
Drug: HSA 
ratio 
Particle size 
(nm) 
Poly 
dispersity 
index 
Observations 
Entrapment 
efficiency 
(%) 
1:20 230.6 0.348 Good drug dispersion 68.45 
1:10 85.5 0.121 Good drug dispersion 77.56 
1:5 -  Precipitation of the drug - 
 
 
 
Table 4: Number of P. Berghei infected mice surviving in each group at the end of 30th 
day (n=5) 
 
Treatment Number of animals survived % Survival 
Untreated Group 0/5 0 
AAN (0.624mg/day;100% dose) 3/5 60 
AAN (0.312mg/day;50% dose) 3/5 60 
		 	
 
 
 
 
 
      Figure 1: Ishikawa Diagram for essential product and process parameters 
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Figure 2: Optimization of HSA nanoparticles  (a) Effect of HSA concentration on particle size of nanoparticles  (b) Effect of pH on 
particle size and polydispersity index of nanoparticles (c) Effect of polysorbate 80 concentration on particle size and encapsulation 
efficiency of nanoparticles (d) 3-D Response surface plot showing the influence of HSA and solvent concentration on particle size of 
nanoparticles (e) 3-D Response surface plot showing the influence of HSA and polysorbate 80 concentration on particle size of 
nanoparticles. HSA: Human serum albumin, P 80: Polysorbate 80 
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Fig 3: Effect of Cryoprotectants on the (a) mean article size before and after lyophilisation and (b) Polydispersity index before and 
after lyophilisation of AAN (mean ± SD, n = 3). W-CRY: Without cryoprotectant; T: Trehelose; M: Mannitol; L:Lactose 
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Fig 4: Fluorescence emission spectra of AAN and BAN following excitation at 280nm 
AAN: Artemether loaded HSA nanoparticle, BAN: blank nanoparticle with HSA only. 
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Figure 5: Characterization of AAN: (a) Transmission electron microscopic image of AAN (b) Scanning electron microscopic image 
of AAN (c) Photograph of AAN before lyophilisation (d) Photograph of AAN after lyophilisation (e) Representation of particle size 
distribution by intensity using photon correlation spectroscopy (f) In-vitro release profile of lyophilised and non lyophilised AAN in 
PBS: Ethanol 50:50 v/v at 370 C (mean ± SD, n = 3) 
 Lyo AAN: Lyophilised artemether loaded HSA nanoparticle, Non lyo-AAN: Artemether loaded HSA nanoparticles prior to 
lyophilisation 
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Figure 6: In vitro erythrocyte haemolysis after treatment with varying dilutions AAN in normal saline (mean ± SD, n = 3) 
AAN: Artemether HSA nanoparticles; Triton X 100 (2%) in normal saline as positive control; Polysorbate 80 (3%) in normal 
saline as reference 
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Figure 7. Dose response curves depicting mean parasitaemia inhibition vs. drug concentration 48 hours after incubation in-vitro 
(mean ± SD, n = 3). ATM: artemether drug only, AAN: Artemether loaded HSA nanoparticle, BAN: blank nanoparticle with HSA 
only. 
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Figure 8: Confocal images showing selective targeting of rhodamine labelled nanoparticles to pRBCs vs. RBCs. Rhodamine labelled 
nanoparticles were added to living co-cultures of P. falciparum-infected RBCs and non infected RBCs and incubated for the indicated times 
before sample preparation for microscopic analysis. Blue and red fluorescence represent DAPI (pRBC) and Rhodamine B (localization of 
AAN), respectively
Figure panels L to R bright field image, DAPI stained Plasmodium nucleus to indicate pRBC, Rhodamine labelled AAN and merged images  
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Figure 9: Mean percent parasitemia in suppressive test against P. berghei infected mice after 
treatment with AAN, BAN and Reference at (a) 100% (b) 50% dose levels, AAN: Artemether 
loaded HSA nanoparticle, BAN: blank nanoparticle with HSA only, Reference: Larinate artesunate 
marketed injection (Values are expressed as mean ± SD n = 5 mice per group) 
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Figure 10: Drug concentration- time profiles in parasitized mice (a) RBC (b) Plasma (mean ± SD, 
n = 6)
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